Regulation of endothelial cell differentiation and transformation by H-Ras

Experimental Cell Research

Volumn 291, Issue 1, 2003, Pages 189-200

  Rennel, Emma ^a   Cross, Michael J ^a   Klint, Peter ^a   Bai, Xianhe ^b   Arbiser, Jack L ^b   Gerwins, Pär ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Angiosarcoma; Differentiation; Endothelium; FGF 2; Proliferation; Ras; Transformation; Tumor

Indexed keywords

FIBRIN; FIBROBLAST GROWTH FACTOR 2; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL CONTACT; CELL DIFFERENTIATION; CELL GROWTH; CELL IMMORTALIZATION; CELL LINE; CELL PROLIFERATION; CELL STIMULATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; GEL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GROWTH INHIBITION; INHIBITION KINETICS; INJECTION; MICROVASCULATURE; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SOLID TUMOR; TUMOR GROWTH;

EID: 0242333895     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(03)00347-1     Document Type: Article

References (52)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:2000;389-395.
4. Javerzat S., Auguste P., Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol. Med. 8:2002;483-489.
5. Malumbres M., Pellicer A. RAS pathways to cell cycle control and cell transformation. Front. Biosci. 3:1998;d887-912.
6. Johnson L., Greenbaum D., Cichowski K., Mercer K., Murphy E., Schmitt E., Bronson R.T., Umanoff H., Edelmann W., Kucherlapati R., Jacks T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11:1997;2468-2481.
7. Koera K., Nakamura K., Nakao K., Miyoshi J., Toyoshima K., Hatta T., Otani H., Aiba A., Katsuki M. K-ras is essential for the development of the mouse embryo. Oncogene. 15:1997;1151-1159.
8. Esteban L.M., Vicario-Abejon C., Fernandez-Salguero P., Fernandez-Medarde A., Swaminathan N., Yienger K., Lopez E., Malumbres M., McKay R., Ward J.M., Pellicer A., Santos E. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell Biol. 21:2001;1444-1452.
9. Umanoff H., Edelmann W., Pellicer A., Kucherlapati R. The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. USA. 92:1995;1709-1713.
10. Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W., Dionne C.A., Jaye M., Rubinstein M., Schlessinger J. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol. Cell Biol. 11:1991;5068-5078.
11. Cross M.J., Lu L., Magnusson P., Nyqvist D., Holmqvist K., Welsh M., Claesson-Welsh L. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. Mol. Biol. Cell. 13:2002;2881-2893.
12. Klint P., Kanda S., Claesson-Welsh L. Shc and a novel 89-kDa component couple to the Grb2-Sos complex in fibroblast growth factor-2-stimulated cells. J. Biol. Chem. 270:1995;23337-23344.
13. Kouhara H., Hadari Y.R., Spivak-Kroizman T., Schilling J., Bar-Sagi D., Lax I., Schlessinger J. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 89:1997;693-702.
14. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways regulation and physiological functions . Endocr. Rev. 22:2001;153-183.
15. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
16. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171:2001;1-10.
17. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis signalling pathways, biological responses and therapeutic inhibition . Trends Pharmacol. Sci. 22:2001;201-207.
18. Henkemeyer M., Rossi D.J., Holmyard D.P., Puri M.C., Mbamalu G., Harpal K., Shih T.S., Jacks T., Pawson T. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 377:1995;695-701.
19. Lai K.M., Pawson T. The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo. Genes Dev. 14:2000;1132-1145.
20. Wojnowski L., Zimmer A.M., Beck T.W., Hahn H., Bernal R., Rapp U.R., Zimmer A. Endothelial apoptosis in Braf-deficient mice. Nat. Genet. 16:1997;293-297.
21. Rak J., Kerbel R.S. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol. 333:2001;267-283.
22. Klafter R., Arbiser J.L. Regulation of angiogenesis and tumorigenesis by signal transduction cascades lessons from benign and malignant endothelial tumors . J. Investig. Dermatol. Symp. Proc. 5:2000;79-82.
23. Meadows K.N., Bryant P., Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires ras activation. J. Biol. Chem. 276:2001;49289-49298.
24. Takahashi T., Ueno H., Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 18:1999;2221-2230.
25. Kanda S., Landgren E., Ljungstrom M., Claesson-Welsh L. Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice. Cell Growth Differ. 7:1996;383-395.
26. Venetsanakos E., Mirza A., Fanton C., Romanov S.R., Tlsty T., McMahon M. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp. Cell Res. 273:2002;21-33.
27. Rennel E., Gerwins P. How to make tetracycline-regulated transgene expression go on and off. Anal. Biochem. 309:2002;79.
28. de Rooij J., Bos J.L. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene. 14:1997;623-625.
29. Koolwijk P., van Erck M.G., de Vree W.J., Vermeer M.A., Weich H.A., Hanemaaijer R., van Hinsbergh V.W. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. 132:1996;1177-1188.
30. Jat P.S., Noble M.D., Ataliotis P., Tanaka Y., Yannoutsos N., Larsen L., Kioussis D. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc. Natl. Acad. Sci. USA. 88:1991;5096-5100.
31. Langley R.R., Ramirez K.M., Tsan R.Z., Arsdall M.V., Nilsson M.B., Fidler I.J. Tissue-specific microvascular endothelial cell lines from H-2Kb-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 63:2003;2971-2976.
32. Broome M.A., Courtneidge S.A. No requirement for src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen. Oncogene. 19:2000;2867-2869.
33. Collen A., Hanemaaijer R., Lupu F., Quax P.H., van Lent N., Grimbergen J., Peters E., Koolwijk P., van Hinsbergh V.W. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood. 101:2003;1810-1817.
34. Yashima R., Abe M., Tanaka K., Ueno H., Shitara K., Takenoshita S., Sato Y. Heterogeneity of the signal transduction pathways for VEGF-induced MAPKs activation in human vascular endothelial cells. J. Cell Physiol. 188:2001;201-210.
35. Zubilewicz A., Hecquet C., Jeanny J.C., Soubrane G., Courtois Y., Mascarelli F. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells a comparative study with VEGF . Oncogene. 20:2001;1403-1413.
36. Cox A.D., Der C.J. Farnesyltransferase inhibitors promises and realities . Curr. Opin. Pharmacol. 2:2002;388-393.
37. Klint P., Kanda S., Kloog Y., Claesson-Welsh L. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene. 18:1999;3354-3364.
38. Bhagwat S.V., Petrovic N., Okamoto Y., Shapiro L.H. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood. 101:2003;1818-1826.
39. Maru Y., Yamaguchi S., Takahashi T., Ueno H., Shibuya M. Virally activated Ras cooperates with integrin to induce tubulogenesis in sinusoidal endothelial cell lines. J. Cell Physiol. 176:1998;223-234.
40. Fox P.L., Sa G., Dobrowolski S.F., Stacey D.W. The regulation of endothelial cell motility by p21 ras. Oncogene. 9:1994;3519-3526.
41. Zimrin A.B., Villeponteau B., Maciag T. Models of in vitro angiogenesis endothelial cell differentiation on fibrin but not matrigel is transcriptionally dependent . Biochem. Biophys. Res. Commun. 213:1995;630-638.
42. Ali B.R., Pal A., Croft S.L., Taylor R.J., Field M.C. The farnesyltransferase inhibitor manumycin A is a novel trypanocide with a complex mode of action including major effects on mitochondria. Mol. Biochem. Parasitol. 104:1999;67-80.
43. Gu W.Z., Tahir S.K., Wang Y.C., Zhang H.C., Cherian S.P., O'Connor S., Leal J.A., Rosenberg S.H., Ng S.C. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer. 35:1999;1394-1401.
44. Vincent L., Soria C., Mirshahi F., Opolon P., Mishal Z., Vannier J.P., Soria J., Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler. Thromb. Vasc. Biol. 22:2002;623-629.
45. Williams R.L., Risau W., Zerwes H.G., Drexler H., Aguzzi A., Wagner E.F. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell. 57:1989;1053-1063.
46. Arbiser J.L., Moses M.A., Fernandez C.A., Ghiso N., Cao Y., Klauber N., Frank D., Brownlee M., Flynn E., Parangi S., Byers H.R., Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA. 94:1997;861-866.
47. MacKenzie K.L., Franco S., Naiyer A.J., May C., Sadelain M., Rafii S., Moore M.A. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene. 21:2002;4200-4211.
48. Burger A.M., Fiebig H.H., Kuettel M.R., Lautenberger J.A., Kung H.F., Rhim J.S. Effect of oncogene expression on telomerase activation and telomere length in human endothelial, fibroblast and prostate epithelial cells. Int. J. Oncol. 13:1998;1043-1048.
49. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
50. Suzuki E., Nishimatsu H., Nagata D., Satonaka H., Goto A., Omata M., Fujita T., Nagai R., Hirata Y. Constitutive activation of proto-oncogen protein p21 induces cell cycle arrest in the G1 phase in contact-inhibited vascular endothelial cells. Hypertens. Res. 25:2002;773-778.
51. Spyridopoulos I., Isner J.M., Losordo D.W. Oncogenic ras induces premature senescence in endothelial cells role of p21(Cip1/Waf1) . Basic Res. Cardiol. 97:2002;117-124.
52. M.J. Marion, S. Boivin-Angele, Vinyl chloride-specific mutations in humans and animals, IARC Sci. Publ. (1999) 315-324.